Background: The aim of the present study was to assess the association between M235T polymorphism and heart failure using a meta-analysis. Methods: A literature search of Google Scholar, PubMed, the Cochrane Library and the China National Knowledge Infrastructure database (January 1990-April 2012) was performed for relevant studies. Statistical analyses were carried out using the Stata 12.0 to combine all the relevant studies. Summary odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated in a fixed-effects model and a random-effects model when appropriate. The pooled ORs were performed under the allelic contrast (T vs M), the dominant (TT + MT vs. MM) and the recessive models (TT vs MT + MM). Begg's test was used to measure publication bias. Results: A total of six case-control studies including 842 patients and 1054 controls were enrolled in this meta-analysis. Overall, there was a significant association between angiotensinogen (AGT) gene M235T polymorphism and risk of heart failure in the subgroup analysis under the allelic contrast (T vs M: OR = 1.48, 95% CI: 1.04-2.11) and the dominant model (TT+MT vs MM: OR=1.67, 95% CI: 1.13-2.46) in the Caucasian population. Conclusions: The current meta-analysis suggests that M235T polymorphism might be associated with increased risk of heart failure in Caucasians.
Introduction
Heart failure is a commonly encountered neurohormonal and hemodynamic syndrome with reduced cardiac contractility and modified neurohumoral activation. 1, 2 It is a major cause of morbidity and mortality worldwide, and it is estimated that by 2030 an additional 3 million people will have developed heart failure, a 25.0% increase in prevalence from 2010 in America. 3 Over the past few years, the following risk factors have been shown to be related to heart failure outcome: age, gender, hypertension, coronary artery disease, diabetes, obesity and lifestyle. In addition, the pathogenesis of heart failure is influenced by multiple genetic factors. 4 In patients with cardiovascular disease, activity of the renin-angiotensin system (RAS) is often increased. 5 The RAS is a key element in pressure/volume homeostasis, and it plays an important role in the regulation of blood pressure and in cardiac function. 6 Angiotensinogen (AGT) is the component of RAS that is released from the liver and is cleaved by renin. The AGT gene M235T polymorphism (a methionine to threonine amino acid substitution at codon 235 designated the M and T alleles) has been associated with elevated levels of AGT, with 235TT homozygotes having between 10% and 20% more plasma AGT than in 235MM individuals. 7 To date, M235T polymorphism has been linked to susceptibility to hypertension, coronary heart disease and atrial fibrillation. [8] [9] [10] In addition, several studies found an association between M235T polymorphism and heart failure while others did not, suggesting that it may serve as a possible risk factor for heart failure. In the The M235T polymorphism in the angiotensinogen gene and heart failure: a meta-analysis present study, we investigated whether the M235T polymorphism is associated with heart failure risk by performing a meta-analysis.
Materials and methods

Study selection criteria
The titles and abstracts of all citations identified by the literature search were reviewed. Selection criteria were then applied to all potentially relevant studies. The selection criteria for inclusion in the meta-analysis were: a) Evaluation of the association of AGT gene M235T polymorphism and heart failure; b) had original data from case-control studies; c) the heart failure diagnosis complied with New York Heart Association (NYHA) functional class II-IV; and (d) studies that included sufficient genotype data for extraction.
Search strategy for identification of studies
The Google Scholar, PubMed, Cochrane Library and China National Knowledge Infrastructure database were searched for all articles on the association between M235T polymorphism and heart failure risk (January 1990-April 2012). The following keywords were used: "angiotensinogen/ AGT," "polymorphism/genetic" and "heart failure/HF." In order to identify the relevant publications, the references cited in the research papers were also scanned. In the case of duplicate reports, or studies obviously reporting results from the same study population, only the latest published results were used. The reference lists of major textbooks, review articles and included articles were identified through manual searches to find other potentially eligible studies.
Data extraction
Two investigators (Song Chen and Hong-Wei Wang) extracted the data from the studies meeting the selection criteria, and disagreements were resolved in consultation with a third reviewer (Li-Li Zhang). Data were extracted concerning (a) first author; (b) year of publication; (c) race; (d) country; (e) number of patients and controls enrolled in the study; (f) number of genotypes; and (g) evidence of Hardy-Weinberg equilibrium (HWE) in controls. All of the data are shown in Table 1 .
Statistical methods
A Q-test was performed to evaluate between-study heterogeneities, I 2 values of 25, 50 and 75% were defined as low, moderate and high estimates, respectively. 16 If heterogeneity was found among the studies (p > 0.10 or I 2 < 50%), the pooled OR was estimated by the fixed-effects model (Mantel-Haenszel method), otherwise, the random-effects (DerSimonian and Laird method) model was used to estimate the pooled OR. 17 When study groups are homogeneous, the two models are similar, but if this is not the case the random-effects model usually provides wider CIs than the fixed-effects model. The random-effects model is best used in the between-study heterogeneity. 18 Subgroup analysis based on ethnicity and sample size were used to explore and explain the diversity among the results of different studies. Different ethnicities were categorized as Asian, Caucasian and African. Sensitivity analysis was performed to assess the stability of the results by excluding one study with genotype distributions not in HWE. 11 Only one study was performed in African patients; therefore, the result of subgroup analysis by ethnicity could not be reliable for Africans. Publication bias was investigated by Begg's funnel plot; p<0.05 was considered as statistically significant publication bias. All p values were two tailed. Meta-analysis was performed using the STATA package version 12.0 (Stata Corporation, College Station, TX, USA). The power of each study was computed as the probability of detecting an association between the M235T polymorphism and heart failure using a significance level of 0.05, assuming an OR of 1.5 (small-effect size). Power analysis was 
Results
A total of 31 papers were retrieved through the literature search, of which six papers were eligible based on the study selection criteria (Figure 1 , Table 1 ). Of these, 19 papers were excluded because they did not satisfy the inclusion criteria, one paper had a duplicated publication, two papers did not have a control group, and three papers included other diseases (hypertension or coronary artery disease). Finally, six case-control studies in five articles were gathered including 842 patients and 1054 controls, [11] [12] [13] [14] [15] containing the population studies of two Caucasians, 12, 14 three Asians [13] [14] [15] and one South African. 11 The genotype distributions among the controls of all studies were consistent with HWE except for one study. 11 Of the six retrospective studies, four papers used population-based controls, [11] [12] [13] [14] and two studies of one paper used hospital-based controls. 15 The study by Goldbergova et al. 12 used the mismatch method, and the other studies used polymerase chain reaction/restriction fragment length polymorphism for genotyping. The statistical power of these six studies ranged from 21.8% to 66.5%. None of the studies had a statistical power exceeding 80%.
Quantitative synthesis
Overall, the M235T polymorphism was not associated with heart failure risk in the population as a whole. When stratified for ethnicity, a significantly increased risk was observed in the Caucasian population (T vs M: OR = 1.48, 95% CI: 1.04-2.11; TT+MT vs MM: OR=1.67, 95% CI: 1.13-2.46). Moreover, when limiting the analysis to the study sample size (> 300), we detected no significant association (Figure 2 , Table 2 ). Sensitivity analysis was performed by removing the study by Tiago et al. 11 because the genotype distribution in the control groups deviated from HWE, resulting in significantly altered results (T vs M: OR=1.36, 95% CI: 1.06-1.74; TT vs MT+MM: OR=1.52, 95% CI: 1.02-2.25). The results show that there was heterogeneity among studies in overall comparisons (Table 2) . Because the study participants by Tiago et al. were African, the data led us to the conclusion that the heterogeneity was closely related to ethnicity. In contrast, sample size was not correlated with the heterogeneity.
Publication bias
The funnel plot and Begg's test was used to assess the publication bias. There was no evidence of publication bias in our study ( Table 2 ). The results implied that the publication bias was low in the present meta-analysis.
Discussion
Although several research studies have evaluated the association between the AGT gene M235T polymorphism and heart failure, the specific association is still controversial. Sanderson et al. were the first to explore the association of M235T polymorphism with heart failure in a cohort of Chinese patients, and the result showed that M235T polymorphism did not appear to be related to survival or severity of the syndrome. 20 In contrast to the above study, Pilbrow et al. tested the association between M235T polymorphism and heart failure risk in a cohort in New Zealand and suggested that M235T polymorphism may provide prognostic information for long-term survival in heart failure patients. 21 Our meta-analysis quantitatively assessed the association between M235T polymorphism and heart failure risk. The current meta-analysis included 842 heart failure patients and 1054 controls and explored the association between the M235T polymorphism of the AGT gene and heart failure risk. To the best of our knowledge, this is the first meta-analysis assessing the relationship between M235T polymorphism and the risk of heart failure. Significant association was observed between M235T polymorphism and heart failure under the allelic contrast (T vs M: OR = 1.48, 95% CI: 1.04-2.11) and the dominant model (TT+MT vs MM: OR=1.67, 95% CI: 1.13-2.46) in the Caucasian population. Conversely, no associations were detected in Asians, partly owing to a possible role of ethnic differences in genetic backgrounds and the environment in which they lived, and partly because of the difference of plasma AGT level. Previous meta-analyses have shown that plasma AGT level was significantly increased under the homozygote comparison (TT vs MM) and the heterozygote comparison (MT vs MM) in Caucasians, and plasma AGT level was not significantly different in comparison to the M235T MM genotype in Asians, 22 indicating that plasma AGT level was increased in subjects carrying the 235T allele in Caucasians.
The mechanism of how the AGT gene M235T polymorphism relates to heart failure risk in Caucasians is still unclear. The serum AGT levels were shown to be increased within the heart and kidney in subjects carrying the 235T allele, 7 and AGT interacts with renin to produce angiotensin II. 23 Angiotensin II has also been shown to increase myocardial protein synthesis, 24 to promote cardiac myocyte growth, 25 to activate cardiac fibrosis and specific intracellular signaling cascades that result in cardiac hypertrophy. 26 Furthermore, angiotensin II activates vascular cell apoptosis, contributing to vascular remodeling and cardiomyocyte loss in ischemia-reperfusion, rendering these organs more vulnerable to adverse cardiac remodeling and renal impairment because of the occurrence of heart failure. 27 In addition, the linkage disequilibrium of G(-6)A and M235T, M235T and T174M in exon 2 of the AGT gene may synergistically increase the risk of heart failure. 12, 21 Several limitations of our study should be noted: First, Jeunemaitre et al. showed that the M235T polymorphism was significantly associated with increased serum AGT levels in women only, and gender-based subgroup analysis could not be investigated reliably for lack of information for the data analysis. 28 Second, the effect of potential genegene and gene-environment interactions could not be addressed as well in this meta-analysis. Additionally, meta-analysis is retrospective research that is subject to methodological limitations.
In conclusion, our study indicated that the M235T polymorphism may be associated with heart failure risk in Caucasians. Further studies with the consideration of gene-gene and gene-environment interactions should be performed to further evaluate this association. 
